Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Beluga Group shipments in Q1 increased relative to 2021, but did not reach the record high of 2022

4/11/23 BELU

Sberbank reported for Q1 2023 according to RAS

4/11/23 SBER

Novatek asks the government to reduce additional taxes for Yamal LNG

4/11/23 NVTK

Sistema sells East-West United Bank

4/11/23 AFKS

Inter RAO will build a 550 MW thermal power plant for the Eastern landfill

4/11/23 IRAO

Sistema reported for 2022 according to IFRS

4/10/23 AFKS

Board of Directors of TNS power Rostov-on-Don recommended that dividends be paid for 2022

4/10/23 RTSB

Samolet will start low-rise projects in Istra and Pushkino in December 2023

4/10/23 SMLT

Cherkizovo invests ₽1 billion to modernize its feed mill in the Moscow region

4/10/23 GCHE

Board of Directors of TNS Energy Kuban recommended that dividends for 2022

4/10/23 KBSB